Kemadren

Procyclidine, the active ingredient in Kemadren, is an anticholinergic (muscarinic antagonist) presented as an oral tablet for systemic use. It reduces excessive cholinergic activity in the basal ganglia and is employed as adjunct therapy in Parkinson’s disease and to treat drug‑induced extrapyramidal symptoms such as akathisia and dystonia.

GNH USA supplies Kemadren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for regulated markets.

Kemadren (procyclidine) is used to address disorders involving excessive cholinergic activity in the central nervous system. - Parkinson's disease (adjunct therapy): Improves motor control by balancing acetylcholine and dopamine activity in the basal ganglia. - Drug‑induced extrapyramidal symptoms: Alleviates rigidity, tremor, and bradykinesia caused by antipsychotic medications. - Akathisia: Reduces restlessness and the urge to move associated with medication‑induced movement disorders.

Procyclidine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dry mouth: reduced salivary secretion. - Blurred vision: difficulty focusing due to ocular accommodation changes. - Constipation: slowed gastrointestinal motility. - Drowsiness: central nervous system depression.

Serious or Rare Side Effects: - Confusion or delirium: acute cognitive changes. - Hallucinations: visual or auditory disturbances. - Tachycardia: increased heart rate. - Severe allergic reaction: rash, swelling, or anaphylaxis.

When prescribing or dispensing Kemadren, several precautions should be observed to ensure patient safety. - Assess renal and hepatic function: dose may need adjustment in impairment. - Monitor for cognitive changes: anticholinergic burden can affect cognition, especially in the elderly. - Evaluate for glaucoma: anticholinergic effects may worsen intra‑ocular pressure. - Review concomitant anticholinergic drugs: additive effects can increase side‑effects. - Avoid use in patients with known hypersensitivity to procyclidine or other anticholinergics. - Store at ambient temperature: keep below 25 °C, retain in original packaging and protect from moisture.

Procyclidine can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Central nervous system depressants (e.g., benzodiazepines, opioids): may enhance sedation and respiratory depression. - Anticholinergic agents (e.g., atropine, trihexyphenidyl): additive anticholinergic toxicity. - Antihistamines with anticholinergic properties (e.g., diphenhydramine): increase risk of dry mouth, constipation, and confusion.

Moderate Interactions (Monitor Closely): - Antipsychotics (e.g., haloperidol): may reduce therapeutic effect on extrapyramidal symptoms. - Antihypertensives (e.g., beta‑blockers): possible additive effect on heart rate. - Drugs affecting QT interval (e.g., certain antiarrhythmics): monitor cardiac rhythm.